Hand-out
Press Releases
Beacon Therapeutics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for laru-zova (AGTC-501)
RMAT designation provides benefits including enhanced communications with FDA throughout developmentRecognizes preliminary clinical evidence from the Phase 2 DAWN and SKYLINE trials of laru-zova in X-linked retinitis pigmentosa (XLRP)Laru-zova also
